Cost-Effectiveness (Ce) Analysis of Empagliflozin 25mg Versus Sitagliptin 100mg in the Treatment of Patients with type 2 Diabetes Mellitus (T2dm) when added to metformin (Met) from a Mexican Public Institutional Context

Abstract

A61 mg, resulting in ~25% greater 24-hour urinary glucose excretion. In addition, CANA 300 mg may transiently block intestinal SGLT1, delaying glucose absorption and reducing postprandial glucose. METHODS: The IMS CORE Diabetes Model was used to evaluate the cost-effectiveness of CANA 100 and 300 mg versus DAPA 10 mg using Spanish-specific utilities and cost data. Direct costs were reported in euros and an annual discount rate of 3% was applied to costs and effects. The time horizon used for the economic evaluation was 40 years to reflect the chronic nature of the disease. A randomised, controlled trial of CANA in dual therapy and an NMA were sourced for initial patient characteristics and treatment effects. Results were compared with the willingness-to-pay (WTP) threshold reported for Spain (€ 30,000/QALY). RESULTS: CANA 100 mg dominated DAPA in dual therapy, with 0.061 quality-adjusted life years (QALYs) gained. CANA 300 mg was cost-effective compared to DAPA 10 mg in dual therapy with a cost-effectiveness ratio below the WTP threshold in Spain; QALYs gained were 0.084. CONCLUSIONS: These results suggest that adding CANA 100 or 300 mg instead of DAPA 10 mg in patients inadequately controlled on metformin would result in more efficient use of healthcare resources in the Spanish setting.

<p>Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China</p>

“…[39][40][41] Moreover, some researchers focused on the comparisons between SGLT-2 inhibitors and other drug classes and demonstrated empagliflozin was more cost-effective than sitagliptin and liraglutide. 42,43 Some other studies focused on the similar issue; however, these analyses were either based on indirect model (the IQVIA CORE model uses HbA1c, blood glucose level and BMI as key model inputs, rather than direct cardiovascular outcomes) 44 or with a short time-horizon (1 year). 44 Currently, SGLT-2 inhibitors (with benefit evidence, including empagliflozin) have been recommended by both American Diabetes Association (ADA) and European Society of Cardiology (ESC)/European Association for the Study of Diabetes (EASD) guidelines 45,46 as part of the glucose-lowering regimen independent of HbA1c among T2DM patients who have established atherosclerotic cardiovascular disease or indicators of high risk, established kidney disease, or heart failure.…”